[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341173-105":59,"doc-detail-341173-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","blockade-of-histamine-receptor-h1-augments-immune-checkpoint-therapy-by-enhancing-mhc-i-expression-in-pancreatic-cancer-cells","Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells","","Immune checkpoint blockade (ICB) offers strong benefit for some cancers, yet efficacy against pancreatic ductal adenocarcinoma (PDAC) remains limited. The study investigates histamine receptor H1 (HRH1) and its influence on ICB response in PDAC. HRH1 expression was measured using public datasets and immunohistochemistry, with functional testing via HRH1 antagonists and HRH1-targeting shRNA alongside αPD-1 in orthotopic models to evaluate changes in MHC-I and cytotoxic CD8+ T-cell infiltration.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/blockade-of-histamine-receptor-h1-augments-immune-checkpoint-therapy-by-enhancing-mhc-i-expression-in-pancreatic-cancer-cells/341173/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/blockade-of-histamine-receptor-h1-augments-immune-checkpoint-therapy-by-enhancing-mhc-i-expression-in-pancreatic-cancer-cells/341173.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why did the study focus on immune checkpoint blockade in PDAC?","Question",{"text":113,"@type":114},"ICB is highly effective in some cancers, but its benefit for PDAC is limited. Improving the ICB effect could enhance PDAC prognosis.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was HRH1 assessed and tested in pancreatic cancer cells?",{"text":118,"@type":114},"HRH1 expression was evaluated using public data analysis and immunohistochemical staining. HRH1 impact was further tested with HRH1 antagonists and HRH1-targeting small hairpin RNA (shRNA).",{"name":120,"@type":111,"acceptedAnswer":121},"What was the effect of combining HRH1 blockade with PD-1 inhibition?",{"text":122,"@type":114},"Combined HRH1 and αPD-1 inhibition enhanced cytotoxic CD8+ T-cell penetration and treatment efficacy, overcoming resistance to ICB therapy in the orthotopic model.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},341173,1790148084,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Zhong et al. J Exp Clin Cancer Res (2024) 43:138 [https://doi.org/10.1186/s13046-024-03060-5](https://doi.org/10.1186/s13046-024-03060-5)  \nJournal of Experimental & Clinical Cancer Research  \n RESEARCH Open Access  \nBlockade of histamine receptor H1  \naugments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells  \nPingShan Zhong1, Kohei Nakata 1,2,3* , Koki Oyama1, Nobuhiro Higashijima 1, Akiko Sagara1, Satomi Date 1, HaiZhen Luo 1, Masataka Hayashi 1, Akihiro Kubo 1, ChenYi Wu1, Shan He 1, Takeo Yamamoto4, Kazuhiro Koikawa 1, Chika Iwamoto 1, Toshiya Abe1, Naoki Ikenaga 1, Kenoki Ohuchida1, Takashi Morisaki5, Yoshinao Oda4,  \nKeiji Kuba6 and Masafumi Nakamura 1  \nAbstract  \nBackground Although immune checkpoint blockade (ICB) therapy has proven to be extremely effective at managing certain cancers, its efficacy in treating pancreatic ductal adenocarcinoma (PDAC) has been limited. Therefore, enhancing the effect of ICB could improve the prognosis of PDAC. In this study, we focused on the histamine receptor H1 (HRH1) and investigated its impact on ICB therapy for PDAC.  \nMethods We assessed HRH1 expression in pancreatic cancer cell (PCC) specimens from PDAC patients through public data analysis and immunohistochemical (IHC) staining. The impact of HRH1 in PCCs was evaluated using HRH1 antagonists and small hairpin RNA (shRNA) . Techniques including Western blot, flow cytometry, quantitative reverse transcription polymerase chain reaction (RT-PCR), and microarray analyses were performed to identify the relationships between HRH1 and major histocompatibility complex class I (MHC-I) expression in cancer cells. We combined HRH1 antagonism or knockdown with anti-programmed death receptor 1 (αPD-1) therapy in orthotopic models, employing IHC, immunofluorescence, and hematoxylin and eosin staining for assessment.  \nResults HRH1 expression in cancer cells was negatively correlated with HLA-ABC expression, CD8+ T cells, and cytotoxic CD8+ T cells. Our findings indicate that HRH1 blockade upregulates MHC-I expression in PCCs via cholesterol biosynthesis signaling. In the orthotopic model, the combined inhibition of HRH1 and αPD-1 blockade enhanced cytotoxic CD8+ T cell penetration and efficacy, overcoming resistance to ICB therapy.  \nConclusions HRH1 plays an immunosuppressive role in cancer cells. Consequently, HRH1 intervention may bea promising method to amplify the responsiveness of PDAC to immunotherapy.  \nKeywords Pancreatic cancer cell, Histamine receptor H1, Major histocompatibility complex class I  \n*Correspondence:  \nKohei Nakata  \n[nakata.kohei.678@m.kyushu-u.ac.jp](nakata.kohei.678@m.kyushu-u.ac.jp)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[. The Creative Commons Public Domain Dedication waiver (](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[http://creativecom](http://creativecom)[mons.org/publicdomain/zero/1.0/](mons.org/publicdomain/zero/1.0/)) appli","cbCaidBGfVdO2ATe","https://ap.wps.com/l/cbCaidBGfVdO2ATe","pdf",5169724,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Background\n## Immune checkpoint blockade in PDAC\n## Role of MHC-I and CD8+ T cells\n## Histamine receptors and antihistamines","[{\"question\":\"Why did the study focus on immune checkpoint blockade in PDAC?\",\"answer\":\"ICB is highly effective in some cancers, but its benefit for PDAC is limited. Improving the ICB effect could enhance PDAC prognosis.\"},{\"question\":\"How was HRH1 assessed and tested in pancreatic cancer cells?\",\"answer\":\"HRH1 expression was evaluated using public data analysis and immunohistochemical staining. HRH1 impact was further tested with HRH1 antagonists and HRH1-targeting small hairpin RNA (shRNA).\"},{\"question\":\"What was the effect of combining HRH1 blockade with PD-1 inhibition?\",\"answer\":\"Combined HRH1 and αPD-1 inhibition enhanced cytotoxic CD8+ T-cell penetration and treatment efficacy, overcoming resistance to ICB therapy in the orthotopic model.\"}]","Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells | PDF",1790040712,48,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/803ecf2f6ef5efb2fecce4e8004a424a.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e05b003ba2cddc7b8a341cd3b9fb44d.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb5258b7427ef3dbada9b600c9bbd8e4.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b3e3a8912fa3ab52e38efa0b33730e8b.webp",980,1301]